JOP20250278A1 - مضاد مستقبلات الميلانوكورتين من النوع 2 - Google Patents

مضاد مستقبلات الميلانوكورتين من النوع 2

Info

Publication number
JOP20250278A1
JOP20250278A1 JOJO/P/2025/0278A JOP20250278A JOP20250278A1 JO P20250278 A1 JOP20250278 A1 JO P20250278A1 JO P20250278 A JOP20250278 A JO P20250278A JO P20250278 A1 JOP20250278 A1 JO P20250278A1
Authority
JO
Jordan
Prior art keywords
receptor antagonist
melanocortin receptor
antagonist type
melanocortin
type
Prior art date
Application number
JOJO/P/2025/0278A
Other languages
Arabic (ar)
English (en)
Inventor
Masaki Ogino
Minoru Ikoma
Kohei Asano
Satoshi Sasaki
Hideto Fukushi
Shizuo Kasai
Shigemitsu Matsumoto
Tsuyoshi Maekawa
Naoyoshi Noguchi
Ryoma Hara
Hideki Hirose
Koji Watanabe
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of JOP20250278A1 publication Critical patent/JOP20250278A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOJO/P/2025/0278A 2023-05-16 2025-11-09 مضاد مستقبلات الميلانوكورتين من النوع 2 JOP20250278A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023080580 2023-05-16
PCT/JP2024/017921 WO2024237266A1 (ja) 2023-05-16 2024-05-15 メラノコルチン２型受容体アンタゴニスト

Publications (1)

Publication Number Publication Date
JOP20250278A1 true JOP20250278A1 (ar) 2025-11-09

Family

ID=93519713

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0278A JOP20250278A1 (ar) 2023-05-16 2025-11-09 مضاد مستقبلات الميلانوكورتين من النوع 2

Country Status (13)

Country Link
EP (1) EP4714953A1 (https=)
JP (1) JPWO2024237266A1 (https=)
KR (1) KR20260009350A (https=)
CN (1) CN120858097A (https=)
AR (1) AR132690A1 (https=)
AU (1) AU2024273541A1 (https=)
CL (1) CL2025003547A1 (https=)
CO (1) CO2025012255A2 (https=)
IL (1) IL324502A (https=)
JO (1) JOP20250278A1 (https=)
MX (1) MX2025013542A (https=)
TW (1) TW202509036A (https=)
WO (1) WO2024237266A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360855A1 (en) * 2000-06-28 2004-09-20 Pfizer Products Inc. Melanocortin receptor ligands
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US12479825B2 (en) * 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
JP7734571B2 (ja) 2021-11-30 2025-09-05 株式会社日立製作所 プロセスモデル構築システム、プロセスモデル構築方法

Also Published As

Publication number Publication date
JPWO2024237266A1 (https=) 2024-11-21
EP4714953A1 (en) 2026-03-25
CO2025012255A2 (es) 2025-09-18
CL2025003547A1 (es) 2026-02-20
AR132690A1 (es) 2025-07-23
IL324502A (en) 2026-01-01
KR20260009350A (ko) 2026-01-19
TW202509036A (zh) 2025-03-01
CN120858097A (zh) 2025-10-28
MX2025013542A (es) 2025-12-01
AU2024273541A1 (en) 2025-11-06
WO2024237266A1 (ja) 2024-11-21

Similar Documents

Publication Publication Date Title
MY209784A (en) Heterocyclic compound and use thereof
JOP20210097B1 (ar) مركبات 2-أمينو-n-أريل غير متجانس-نيكوتيناميد كمثبطات nav1.8
JOP20230138A1 (ar) مثبطات prmt5
MY202221A (en) Heterocyclic compound and use thereof
MX2023013339A (es) Inhibidor del factor b del complemento, y composicion farmaceutica del mismo, metodo de preparacion del mismo y uso del mismo.
JOP20220342A1 (ar) مركبات 2-أوكسو إيميدازوليدين -4- كربوكساميد كمثبطات لـ nav1.8
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2024000067A1 (es) Compuestos antivirales
MX389142B (es) Compuestos espiro triciclicos.
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
ZA202100352B (en) Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
MX2025004831A (es) Compuesto heterociclico
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
MX2022009059A (es) Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a.
PH12021552004A1 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
MY197561A (en) Composition for increasing expression of pgc-1?
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2022002443A (es) Compuestos inhibidores de perk.
JOP20220125A1 (ar) مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها
CL2024003171A1 (es) Gamma-hidroxibutirato que administra compuestos y procesos para su fabricación y uso
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.